Northwest Biotherapeutics’ DCVax personalised cancer vaccine can improve survival for patients with brain cancer and prostate cancer, according to a report by the Matrix Group.

There was also a delayed time-to-progression for both cancers, the document adds.

The DCVax-Prostate vaccine showed median survival of 38.7 months in Phase I/II studies, with 64% of patients surviving for three years.

The report noted that high dendritic cell purity and the single-batch bulk manufacturing process are the competitive advantages of the Northwest Biotherapeutics technology.

DCVax personalised cancer vaccine has been cleared by US Food and Drug Administration to begin a Phase III clinical trial.